Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 2, 2010, Pages 197-202

  Moses, M ^a   Zachariah, R ^b   Tayler Smith, K ^b   Misinde, D ^a   Foncha, C ^a   Manzi, M ^b   Bauerfeind, A ^b   Mwagomba, B ^c   Kwanjana, J ^c   Harries, A D ^d,e  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b MSF   (Belgium)

^c MINISTRY OF HEALTH   (Malawi)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Alanine transferase; HIV; Malawi; Nevirapine; Rifampicin; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; NEVIRAPINE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIAL; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAWI; MALE; MIXED INFECTION; MORTALITY; MUSCLE WEAKNESS; NEWBORN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS LOAD; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; COHORT STUDIES; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALAWI; MALE; NEVIRAPINE; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS; VIRAL LOAD; YOUNG ADULT;

EID: 77049086840     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kwanjana J H, Harries A D, Gausi F, Nyangulu D S, Salaniponi F M L. TB-HIV seroprevalence in patients with tuberculosis in Malawi. Malawi Medical J 2001; 13: 7-10.
2. Van Oosterhout J J, Kumwenda J J, Beadsworth M. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther 2007; 12: 515-521.
3. Ministry of Health and Population and National AIDS Commission. Guidelines for the use of anti-retroviral therapy in Malawi. 2nd ed. Lilongwe, Malawi: Ministry of Health and Population, 2006.
4. Ministry of Health and Population. Manual of the National Tuberculosis Control Programme of Malawi. 5th ed. Lilongwe, Malawi: Ministry of Health and Population, 2002.
5. Finch C K, Christman C R, Baciewicz A M, Self T H. Rifampicin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162: 985-992.
6. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings. Towards universal access. Recommendations for a public health approach. Geneva, Switzerland: WHO, 2006.
7. Havlir D, Cheeseman S H, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-545.
8. Ribera E, Pou L, Lopez R M, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquired Immune Defic Syndr 2001; 28: 450-453.
9. Dean G L, Back D J, de Ruiter A. Impact of tuberculosis therapy on nevirapine trough plasma concentrations. AIDS 1999; 13: 2489-2490.
10. Manosuthi W, Ruxrungtham K, Likanonsakul S, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007; 44: 141-144.
11. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43: 253-255.
12. Shipton L K, Wester C W, Stock S, et al. Safety and efficacy of nevirapine and efavirinz based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009; 13: 360-366.
13. National Statistics Office. Population census report 2008, Lilongwe, Malawi: NSO, 2008.
14. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/2003. 313. Geneva, Switzerland: WHO, 2003.
15. Zachariah R, Teck R, Buhendwa L, et al. Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg 2007; 101: 79-84.
16. Wensing M J, Boucher A B. Worldwide transmission of drug-resistant HIV. AIDS 2003; 5: 140-155.
17. Ivers C L, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-limited settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41: 217-224.
18. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when co-administered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
19. Lee P K, Kieffer T L, Siliciano R F, Nettles R E. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006; 57: 803-805.
20. Zachariah R, Harries A D, Manzi M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PloS One 2006; 1: el21.
21. Bell D J, Kapitao Y, Sikwese R, van Oosterhout J, Lalloo D G. Adherence to antiretroviral therapy in patients receiving free treatment from a government hospital in Blantyre, Malawi. J Acquir Immune Defic Syndr 2007; 45: 560-563.
22. Oliva J, Moreno S, Sanz J, et al. Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis. AIDS 2003; 17: 637-638.
23. Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001; 5: 1000-1005.